|
|
Post by centralcoastinvestor on Oct 25, 2023 17:56:43 GMT -5
Good Afternoon All, Today Laborer75 from stocktwits posted this recent interview of Michael Castagna. I listened to the whole interview and thought it was well worth it. I had forgotten that Mike’s father died from diabetes complications. Also, Mike has diabetes himself and apparently uses Afrezza. The good news, Mike believes in Afrezza and it isn’t going anywhere. I think he has a game plan in place to sell Afrezza but we need to wait for the results of the Afrezza kids trial. Mike is well aware of the problems associated with selling Afrezza and I think that understanding well help a lot in the future. We just need more money to advertise. That is where sales of Tyvaso DPI come in. In fact, Tyvaso sales revenue is basically funding the company without any need for raising funding in the capital markets. Which is nearly impossible now anyway. See the link below to listen to this recent podcast. Thanks. www.ivoox.com/episode-254-michael-castagna-ceo-of-mannkind-audios-mp3_rf_118374742_1.html |
|
|
|
Post by cppoly on Oct 26, 2023 7:06:32 GMT -5
Is there a way to listen without having to download this app?
Edit: never mind, on a desktop website you can listen. Not sure why it was directing me to download an app on my mobile.
|
|
|
|
Post by agedhippie on Oct 26, 2023 14:39:10 GMT -5
... I think he has a game plan in place to sell Afrezza, but we need to wait for the results of the Afrezza kids trial. Mike is well aware of the problems associated with selling Afrezza and I think that understanding will help a lot in the future. We just need more money to advertise. ... I don't see the kids trials really altering the adult market. What it will do is grow the total market by now including kids. I would expect the increase to be in-line with the market share of the adult market, maybe a bit better if the results are good. The endos still need to see hard data that Afrezza can match the AID pumps they are giving kids right now as those pumps are turning in good numbers with minimal effort. The Type 1 market, which is where Mike sees Afrezza according to the Morgan Stanley conference, is not moved by insulin advertising. To get anywhere with that market you are going to need to get endos to want to prescribe, and insurers to provide cover - those will not be altered by retail adverts, it takes data. It is an incredibly conservative and slow changing market because this is literally people's lives so screwing can be fatal rather than inconvenient. In Medicare the $35 co-pay cap is going to make insurers very reluctant to cover Afrezza. We have already seen the formularies for the three largest Medicare insurers and Afrezza is completely absent. You only get a $35 co-pay cap if the insulin is covered. Next year the list price on Humalog will be $66 list for a vial of insulin. The same amount of Afrezza is 100s of dollars and insurers do not want to eat that difference hence the lack of coverage. |
|
|
|
Post by mytakeonit on Oct 26, 2023 17:30:07 GMT -5
Somebody must like it ... MNKD up 16 cents in the after hours.
But, that's mytakeonit
|
|
|
|
Post by cretin11 on Oct 26, 2023 17:54:30 GMT -5
Somebody must like it ... MNKD up 16 cents in the after hours. But, that's mytakeonit Yes! We get to celebrate $4.20 yet AGAIN!? Count me in! 🎉 |
|
|
|
Post by mymann on Oct 26, 2023 19:43:56 GMT -5
Somebody must like it ... MNKD up 16 cents in the after hours. But, that's mytakeonit Yes! We get to celebrate $4.20 yet AGAIN!? Count me in! 🎉 Back down 1 cent. Somebody didn't like what Mike said. I was getting so excited but as usual, they giveth and they taketh. |
|
|
|
Post by centralcoastinvestor on Oct 26, 2023 23:57:23 GMT -5
... I think he has a game plan in place to sell Afrezza, but we need to wait for the results of the Afrezza kids trial. Mike is well aware of the problems associated with selling Afrezza and I think that understanding will help a lot in the future. We just need more money to advertise. ... I don't see the kids trials really altering the adult market. What it will do is grow the total market by now including kids. I would expect the increase to be in-line with the market share of the adult market, maybe a bit better if the results are good. The endos still need to see hard data that Afrezza can match the AID pumps they are giving kids right now as those pumps are turning in good numbers with minimal effort. The Type 1 market, which is where Mike sees Afrezza according to the Morgan Stanley conference, is not moved by insulin advertising. To get anywhere with that market you are going to need to get endos to want to prescribe, and insurers to provide cover - those will not be altered by retail adverts, it takes data. It is an incredibly conservative and slow changing market because this is literally people's lives so screwing can be fatal rather than inconvenient. In Medicare the $35 co-pay cap is going to make insurers very reluctant to cover Afrezza. We have already seen the formularies for the three largest Medicare insurers and Afrezza is completely absent. You only get a $35 co-pay cap if the insulin is covered. Next year the list price on Humalog will be $66 list for a vial of insulin. The same amount of Afrezza is 100s of dollars and insurers do not want to eat that difference hence the lack of coverage. I agree with much of what you are saying above. It has been incredibly difficult to sell Afrezza without data and key opinion leaders (KOL). At around minute 16 or so Mike addressed that issue. For the Pediatric Trials, MannKind is using 40 of the top diabetes centers in the US. None outside of the US. So when the results are known and the data is available, then the KOLs from these centers will be advocates of Afrezza. Additionally, for the Pump Switch trial, MannKind is using 20 of the top diabetes centers. Mike’s plan is that that the new data from the pediatrics trial along with the pump switch trial combined with the thought leaders will move the needle. It sounds like a good plan to me. |
|
|
|
Post by JEvans on Oct 27, 2023 10:48:53 GMT -5
I don't see the kids trials really altering the adult market. What it will do is grow the total market by now including kids. I would expect the increase to be in-line with the market share of the adult market, maybe a bit better if the results are good. The endos still need to see hard data that Afrezza can match the AID pumps they are giving kids right now as those pumps are turning in good numbers with minimal effort. The Type 1 market, which is where Mike sees Afrezza according to the Morgan Stanley conference, is not moved by insulin advertising. To get anywhere with that market you are going to need to get endos to want to prescribe, and insurers to provide cover - those will not be altered by retail adverts, it takes data. It is an incredibly conservative and slow changing market because this is literally people's lives so screwing can be fatal rather than inconvenient. In Medicare the $35 co-pay cap is going to make insurers very reluctant to cover Afrezza. We have already seen the formularies for the three largest Medicare insurers and Afrezza is completely absent. You only get a $35 co-pay cap if the insulin is covered. Next year the list price on Humalog will be $66 list for a vial of insulin. The same amount of Afrezza is 100s of dollars and insurers do not want to eat that difference hence the lack of coverage. I agree with much of what you are saying above. It has been incredibly difficult to sell Afrezza without data and key opinion leaders (KOL). At around minute 16 or so Mike addressed that issue. For the Pediatric Trials, MannKind is using 40 of the top diabetes centers in the US. None outside of the US. So when the results are known and the data is available, then the KOLs from these centers will be advocates of Afrezza. Additionally, for the Pump Switch trial, MannKind is using 20 of the top diabetes centers. Mike’s plan is that that the new data from the pediatrics trial along with the pump switch trial combined with the thought leaders will move the needle. It sounds like a good plan to me. AGED says or thinks that having a pump attached to your BODY is the easiest best minimal effort for insulin. I (myself) do not agree with that mindset. I like to be free of intrusive attachments to my body. A simple small plastic lightweight breathing device the size of a Bic lighter in my pocket that you can use when you need it, easy peasy. Much more freedom, freedom of the mind, the way God intended you to be. Everyone I know on a pump has issues on a daily basis with the pump. Some are in the hospital once a month because of pump malfunction. Doctors do what's easy, SOC..... regardless of outcome and what serves them best. So until Mike can change that type of mindset when it comes to Afrezza with Doctors, people with diabetes will have to be better educated and be their own advocate. |
|
|
|
Post by uvula on Oct 27, 2023 11:17:49 GMT -5
When someone uses phrases like "everyone I know" it usually means they don't have a lot of data to back up their statements.
Aged is an actual diabetic so his opinions about diabetics are valuable. How he feels about something is probably shared by many others.
|
|
|
|
Post by JEvans on Oct 27, 2023 11:49:32 GMT -5
When someone uses phrases like "everyone I know" it usually means they don't have a lot of data to back up their statements. Aged is an actual diabetic so his opinions about diabetics are valuable. How he feels about something is probably shared by many others. I am not a diabetic. But I have opinions and choices ! So, I ask you then; would you rather have a pump or afrezza ? |
|
|
|
Post by uvula on Oct 27, 2023 12:02:03 GMT -5
Fortunately I'm not a diabetic either. If I were a t2d I would rather take afrezza early on to prevent progression instead of followig the current SOC. If I were a t1d I honestly don't know if I would rather take afrezza or have a pump. But I hope diabetics always have a choice.
How many people do you actually know on pumps? Why do they continue to use pumps? I'm sure pumps can improve but there are reasons why so many T1ds continue to use them.
|
|
|
|
Post by peppy on Oct 27, 2023 12:11:59 GMT -5
Fortunately I'm not a diabetic either. If I were a t2d I would rather take afrezza early on to prevent progression instead of followig the current SOC. If I were a t1d I honestly don't know if I would rather take afrezza or have a pump. But I hope diabetics always have a choice. How many people do you actually know on pumps? Why do they continue to use pumps? I'm sure pumps can improve but there are reasons why so many T1ds continue to use them. I would take Afrezza. Perfect control can be achieved. I think the diabetic feels better when their blood glucose levels are more in the normal range. Not to mention the other body systems. The renal system. Perhaps blood pressure so cardiac system. Blood glucose in the presence of oxygen runs the show. |
|
|
|
Post by centralcoastinvestor on Oct 27, 2023 13:20:37 GMT -5
I am pre-diabetic. I wish I could get Dexcom G7 and Afrezza prescribed to me right now and be covered by insurance. I asked my doctor if that was possible and he literally laughed at me. He is a very good doctor by the way. We need to have all options at our disposal when we know that we are diabetic. I am trying to lower my A1C with a better diet and exercise but diabetes runs in our family.
|
|
|
|
Post by mytakeonit on Oct 27, 2023 13:24:14 GMT -5
I am pre-diabetic also ... and hopefully I stay that way forever.
|
|
|
|
Post by JEvans on Oct 27, 2023 13:25:00 GMT -5
Fortunately I'm not a diabetic either. If I were a t2d I would rather take afrezza early on to prevent progression instead of followig the current SOC. If I were a t1d I honestly don't know if I would rather take afrezza or have a pump. But I hope diabetics always have a choice. How many people do you actually know on pumps? Why do they continue to use pumps? I'm sure pumps can improve but there are reasons why so many T1ds continue to use them. I would take Afrezza. Perfect control can be achieved. I think the diabetic feels better when their blood glucose levels are more in the normal range. Not to mention the other body systems. The renal system. Perhaps blood pressure so cardiac system. Blood glucose in the presence of oxygen runs the show. I know two people on pumps very well. One is a veteran at the VA and the VA doctor hasn't heard of afrezza and he is not one to argue or even learn that there are choices (even though i send them info on afrezza all the time). He has used the needle most his life and he is very good and used to doing that. The last two years he has been on the pump and hates it and goes back and forth with the stab and the pump. But, every time I see him he is out of range and needs to eat or give himself a shot. The other one is on the pump and comes close to dying once or twice a yr and always sick. She is also a stubborn person and just won't listen to common sense about using afrezza. Her Dr also is not a fan and she does what Dr says regardless of the damage that she is having. INSANITY: Doing the same thing over and over and expecting different results. |
|
